Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Cash & Current Investments (2018 - 2025)

Historic Cash & Current Investments for Bio (TELA) over the last 8 years, with Q3 2025 value amounting to $29.7 million.

  • Bio's Cash & Current Investments rose 7174.15% to $29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.7 million, marking a year-over-year increase of 7174.15%. This contributed to the annual value of $52.7 million for FY2024, which is 1271.37% up from last year.
  • Bio's Cash & Current Investments amounted to $29.7 million in Q3 2025, which was up 7174.15% from $35.0 million recorded in Q2 2025.
  • In the past 5 years, Bio's Cash & Current Investments registered a high of $65.8 million during Q1 2021, and its lowest value of $17.3 million during Q3 2024.
  • Moreover, its 5-year median value for Cash & Current Investments was $42.8 million (2025), whereas its average is $43.3 million.
  • Per our database at Business Quant, Bio's Cash & Current Investments skyrocketed by 13540.49% in 2023 and then crashed by 7027.42% in 2024.
  • Quarter analysis of 5 years shows Bio's Cash & Current Investments stood at $43.9 million in 2021, then fell by 4.35% to $42.0 million in 2022, then rose by 11.21% to $46.7 million in 2023, then grew by 12.71% to $52.7 million in 2024, then plummeted by 43.59% to $29.7 million in 2025.
  • Its Cash & Current Investments stands at $29.7 million for Q3 2025, versus $35.0 million for Q2 2025 and $42.8 million for Q1 2025.